PrEP Optimization Among Women to Enhance Retention and Uptake
NCT ID: NCT05626452
Last Updated: 2025-05-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
4000 participants
INTERVENTIONAL
2023-08-10
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Increasing PrEP Awareness and Demand Among Black Cisgender Women
NCT05896423
Optimizing PrEP Utilization Among Alcohol and Other Drug (AOD) Using Women of Color
NCT04018651
Linking Women to PrEP Care
NCT03281343
Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV
NCT03226873
Addressing Health Disparities in Engagement, Retention, and Utilization of PrEP Among South Florida Women of Color
NCT05338996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In our stepped wedge design, each step is 6 months long, and there are 4 waves of intervention implementation (three sites begin the intervention at the same step, a mix from the South and the Midwest, N=12). Three CHC sites will be randomized to each step occurring at 6-month intervals. Each cluster also undergoes a 6-month transition period when the individual clinics will prepare to implement the intervention package.
Although the investigators hypothesize that the effect of this intervention will increase PrEP uptake among participants, the investigators powered this study to ensure that the investigators could detect a range of intervention effectiveness. The investigators used the R statistical package swCRTdesign V3.1 to verify that a sample of 50 participants at 6 different times ("steps") each lasting 6 months, at the 12 CHC sites ("clusters") provides adequate power (\>80%) to detect a change from a baseline of 1% of eligible participants receiving prescriptions for PrEP to 2% with an ICC of 0.2 and a CAC of 0.80.60. This minimum sample size per time interval is one that can easily be met by all of the clinics used as sites in this study (100 eligible participants per calendar year).
A key element of the research infrastructure will be AllianceChicago's uniform EMR system, which is distinguished by the integration of evidence-based practice recommendations into the end user interface to provide clinical decision support at the point of care. AllianceChicago's information technology (IT) team will create a study specific fields to measure study outcomes. The IT team will build custom reports in their data warehouse to access and validate in real-time. Reports will be built to pull data (ICD, CPT/HCPCS, and RXNORM codes, laboratory results, demographic characteristics) from the medical record and billing claims, and will be used to determine implementation success for the RE-AIM outcomes of effectiveness and maintenance. The investigators will utilize the Health Catalyst Tool which already has reports built to monitor PrEP care continuum outcomes. Additional reports will be built to monitor: 1) Participants who receive HIV risk assessment 2) participants who receive PrEP education; 3) participants who receive PrEP navigation; 4) PrEP prescriptions among eligible participants.
Implementation Patient education: CHC staff will perform HIV risk assessment for participants who present at the CHCs for care. HIV risk assessment will consist of asking questions regarding PrEP indications adapted from the USHS guidelines for PrEP (e.g., sexual partners, recent STIs, condom use, drug use, etc). For participants who meet criteria of "PrEP eligibility," patient education regarding PrEP will be provided. Patient education occurs at each clinic visit.
Provider training: Providers will complete 3 sessions of 1-hour virtual trainings regarding PrEP (providing patient education, identifying PrEP-eligible participants, offering PrEP, etc.). CHCs will provide protected time for providers to complete the trainings. Trainings will be virtual but also interactive, including the opportunities for providers to use electronic avatars to practice difficult conversations with virtual participants. Monthly audit and feedback will be provided post-training to measure and support sustained behavior change. The investigators will integrate PrEP outcomes reports into the overall quality metric reporting for each clinic. Every month the medical director of each clinic reviews quality metrics for the clinical site. The medical director reports the metrics during monthly clinic meetings and steps are taken to address any metrics that fall short of the expected benchmark. Data on clinic staff's use of PrEP clinical decision support tools and PrEP care continuum outcomes will be incorporated into standard monthly quality report. During monthly site check-ins, the investigators will review this data with the medical director and clinical champions.
EMR optimization: AllianceChicago will incorporate PrEP clinical decision support, including PrEP indication documentation, PrEP order set, and electronic notifications of PrEP-eligible participants into the CHC's EMR and provide weekly reports of PrEP care continuum outcomes for the CHC to review and act upon.
PrEP navigation: The investigators will work with the CHCs to engage staff in the adapted PrEP support roles using manualized procedures and training. PrEP navigators will meet with participants 2-3 times initially to support PrEP uptake, and will check in with patients monthly thereafter (appointment, refill reminders will be based on participants' own schedules).
Monitoring and Process Evaluation with Feedback: The investigators will track the implementation process and provide feedback and support to the CHC for challenges in implementing the strategies, as well as ongoing feedback on interim outcomes including number of participants who underwent HIV risk assessment, the number who discussed PrEP with a provider, proportion initiating PrEP, and results of provider training. Results will be discussed between the research team and each CHC to understand barriers and identify and document adaptations needed using Stirman's FRAME methodology. Broadly, the investigators will discuss and document (1) what and why the investigators adapted, (2) goals of the adaptation, (3) who was involved in the adaptation process, (4) when the investigators adapted, (5) forms of adaptation, and (6) measurement and evaluation.
Evaluation: Utilizing the RE-AIM framework, the investigators will evaluate the success of the implementation strategies. The investigators will gather feedback from CHC providers, staff, and participants using mixed methods with both quantitative surveys and qualitative interviews. For evaluation of the provider training, The investigators will use the Kirkpatrick four-level training evaluation model. The investigators will use provider-level quantitative surveys to assess the four-levels of training: satisfaction and perceived value (Level 1); knowledge and self-efficacy (Level 2); application of knowledge (Level 3; i.e., number of participants offered PrEP); and effectiveness (Level 4; i.e., the increase in proportion of participants on PrEP). Data regarding number of participants who had PrEP education, discussions, and who initiated and persisted on PrEP will be collected from the EMR with electronic reports developed by AllianceChicago. To assess provider and CHC staff feedback about the implementation strategies, the investigators will use surveys to assess the following measures: Acceptability of Intervention Measure (AIM)), appropriateness (Intervention Appropriateness Measure (IAM)), and feasibility (Feasibility of Intervention Measure (FIM)). In addition, the investigators will recruit 400 participants to complete surveys regarding acceptability (AIM) of the POWER Up strategies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Usual Care
The current mechanisms used at each healthcare site to assess HIV risk/ take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
No interventions assigned to this group
Intervention
Implementation of 1) Patient Education, 2) Provider PrEP training, 3) EMR optimization, and 4) PrEP navigation, and the effect of these intervention components on the ability of each site to assess HIV risk/take a sexual history, assess PrEP eligibility, identify PrEP ineligibility for otherwise PrEP-eligible patients, provide PrEP education, offer PrEP, provide PrEP navigation, measure PrEP uptake, and measure PrEP persistence/retention.
PrEP Education
Education for participants regarding PrEP
Provider training
Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
EMR Optimization
EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
PrEP Navigation
Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
Provider Audit and Feedback
Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PrEP Education
Education for participants regarding PrEP
Provider training
Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
EMR Optimization
EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
PrEP Navigation
Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
Provider Audit and Feedback
Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV-negative
Exclusion Criteria
* HIV-positive
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AllianceChicago
OTHER
Howard Brown Health Center
OTHER
Ann & Robert H Lurie Children's Hospital of Chicago
OTHER
Northwestern University
OTHER
Rush University
OTHER
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jessica Ridgway, MD, MS
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Devlin SA, Ridgway JP, Dawdani A, Enaholo OE, Liegeon G, Kasal N, Pyra M, Hirschhorn LR, Simon J, Haider S, Ducheny K, Johnson AK. Adapting Provider Training and Pre-Exposure Prophylaxis Advertising to Increase Pre-Exposure Prophylaxis Awareness and Uptake Among Black Cisgender Women. AIDS Patient Care STDS. 2023 Dec;37(12):574-582. doi: 10.1089/apc.2023.0188. Epub 2023 Nov 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB21-0971
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.